S1733 The Beneficial Effect of the Immunomodulator Glatiramer Acetate Treatment on Syndecan-1 Expression in Dextran Sodium Sulfate Colitis

Abstract

DSS-induced histopathology of individual (or aggregate) scores for inflammation, crypt damage, ulcerations indicates less mucosal damage in A3AR mice than WT (p<0.01). A3 AR mice are resistant to developing colitis. At 3% DSS A3AR mice lose 5% body-weight compared to 20% in WT and recover faster (p<0.01); at 1.5%, A3AR prevents weight-loss (p<0.05). There is a 2-fold reduction in MPO in A3AR mice (p<0.001); it prevented increase in CD4+ T-cells in lamina propria (p=0.009) and attenuated DSS-induced changes in colon length/weight ratio (p<0.01). There is lower incidence of occult-blood and diarrhea in A3 AR-treated mice (p<0.03; p=0.001). Conclusions: The A3AR modulates colonic motility and evacuation. Disruption of A3AR protects against colitis suggesting activation of A3AR by endogenous adenosine may be injurious in DSS-colitis. The A3AR mechanism is unknown (NIH DK 44179,ARRA-3R01 DK044179-14S).